Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease

Vascular dysfunction has a critical role in Alzheimer’s disease (AD). Recent data from brain imaging studies in humans and animal models suggest that cerebrovascular dysfunction may precede cognitive decline and onset of neurodegenerative changes in AD and AD models. Cerebral hypoperfusion and impaired amyloid β-peptide (Aβ) clearance across the blood–brain barrier (BBB) may contribute to the onset and progression of dementia AD type. Decreased cerebral blood flow (CBF) negatively affects the synthesis of proteins required for memory and learning, and may eventually lead to neuritic injury and neuronal death. Impaired clearance of Aβ from the brain by the cells of the neurovascular unit may lead to its accumulation on blood vessels and in brain parenchyma. The accumulation of Aβ on the cerebral blood vessels, known as cerebral amyloid angiopathy (CAA), is associated with cognitive decline and is one of the hallmarks of AD pathology. CAA can severely disrupt the integrity of the blood vessel wall resulting in micro or macro intracerebral bleedings that exacerbates neurodegenerative process and inflammatory response and may lead to hemorrhagic stroke, respectively. Here, we review the role of the neurovascular unit and molecular mechanisms in vascular cells behind AD and CAA pathogenesis. First, we discuss apparent vascular changes, including the cerebral hypoperfusion and vascular degeneration that contribute to different stages of the disease process in AD individuals. We next discuss the role of the low-density lipoprotein receptor related protein-1 (LRP), a key Aβ clearance receptor at the BBB and along the cerebrovascular system, whose expression is suppressed early in AD. We also discuss how brain-derived apolipoprotein E isoforms may influence Aβ clearance across the BBB. We then review the role of two interacting transcription factors, myocardin and serum response factor, in cerebral vascular cells in controlling CBF responses and LRP-mediated Aβ clearance. Finally, we discuss the role of microglia and perivascular macrophages in Aβ clearance from the brain. The data reviewed here support an essential role of neurovascular and BBB mechanisms in contributing to both, onset and progression of AD.

[1]  B T Hyman,et al.  Progression of Cerebral Amyloid Angiopathy: Accumulation of Amyloid-ß40 in Affected Vessels , 1998, Journal of neuropathology and experimental neurology.

[2]  Holtzman,et al.  Clearance of amyloid beta-peptide from brain: transport or metabolism? , 2000, Nature medicine.

[3]  R. Tanzi,et al.  Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses , 2008, Nature Reviews Neuroscience.

[4]  J. Ringman,et al.  Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. , 2005, Journal of Alzheimer's disease : JAD.

[5]  C. Pieper,et al.  The distribution of cerebrovascular amyloid in Alzheimer’s disease varies with ApoE genotype , 2006, Acta Neuropathologica.

[6]  Da-Zhi Wang,et al.  The serum response factor coactivator myocardin is required for vascular smooth muscle development , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  O. Ottersen,et al.  Immunocytochemical evidence that amyloid β (1–42) impairs endogenous antioxidant systems in vivo , 2003, Neuroscience.

[8]  K. Jellinger,et al.  Alzheimer disease and cerebrovascular pathology: an update , 2002, Journal of Neural Transmission.

[9]  Jeffrey F. Thompson,et al.  Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in Rat , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  M. Rafii,et al.  Agrin and microvascular damage in Alzheimer's disease , 2000, Neurobiology of Aging.

[11]  T. Saido,et al.  Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. , 2006, Neuroscience research.

[12]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[13]  J. C. Torre Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics , 2004, The Lancet Neurology.

[14]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[15]  R. Deane,et al.  Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease , 2009 .

[16]  Dietmar Rudolf Thal,et al.  Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease , 2008, Acta Neuropathologica.

[17]  R. Mayeux,et al.  Atherosclerosis and AD , 2005, Neurology.

[18]  T. Grabowski,et al.  Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy , 2001, Annals of neurology.

[19]  A. Goate,et al.  Clearance of amyloid-beta by circulating lipoprotein receptors. , 2007, Nature medicine.

[20]  C. Iadecola,et al.  Aβ-Induced Vascular Oxidative Stress and Attenuation of Functional Hyperemia in Mouse Somatosensory Cortex , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  T. Miyatake,et al.  Cerebral amyloid angiopathy: A significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly , 1993, Journal of the Neurological Sciences.

[22]  R. Carare,et al.  Lymphatic drainage of the brain and the pathophysiology of neurological disease , 2008, Acta Neuropathologica.

[23]  D. Attwell,et al.  Bidirectional control of CNS capillary diameter by pericytes , 2006, Nature.

[24]  美晴 佐村木,et al.  Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease , 2007 .

[25]  B. Puig,et al.  Oxidative damage of 14-3-3 zeta and gamma isoforms in Alzheimer's disease and cerebral amyloid angiopathy. , 2007, Neuroscience.

[26]  C. Iadecola,et al.  Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. , 2006, Journal of applied physiology.

[27]  Da-Zhi Wang,et al.  Activation of Cardiac Gene Expression by Myocardin, a Transcriptional Cofactor for Serum Response Factor , 2001, Cell.

[28]  D. D'urso,et al.  Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[29]  Jeffrey W. Streb,et al.  Myocardin: a component of a molecular switch for smooth muscle differentiation. , 2002, Journal of molecular and cellular cardiology.

[30]  B. Hyman,et al.  The Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel β-Secretase (BACE1) Substrate* , 2005, Journal of Biological Chemistry.

[31]  S. D. Preston,et al.  Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid β from the human brain , 2003, Neuropathology and applied neurobiology.

[32]  J. Wegiel,et al.  The complex of microglial cells and amyloid star in three-dimensional reconstruction , 2004, Acta Neuropathologica.

[33]  José A Fernández,et al.  Activated protein C inhibits tissue plasminogen activator–induced brain hemorrhage , 2006, Nature Medicine.

[34]  Cornelis J. Stam,et al.  Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease , 2005, NeuroImage.

[35]  D. Holtzman,et al.  Clearance of amyloid β-peptide from brain: transport or metabolism? , 2000, Nature Medicine.

[36]  A. Scheibel,et al.  Alzheimer's disease as a capillary dementia. , 1989, Annals of medicine.

[37]  José A Fernández,et al.  Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. , 2002, Seminars in hematology.

[38]  L. Badimón,et al.  Sterol regulatory element-binding protein-2 negatively regulates low density lipoprotein receptor-related protein transcription. , 2006, Journal of molecular biology.

[39]  T. Hattori,et al.  Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. , 2001, Clinical neuropathology.

[40]  M. D'Andrea,et al.  Aβ peptides can enter the brain through a defective blood–brain barrier and bind selectively to neurons , 2007, Brain Research.

[41]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[42]  J. Koziol,et al.  Focal Cerebral Ischemia Induces Active Proteases That Degrade Microvascular Matrix , 2004, Stroke.

[43]  S. Hickman,et al.  Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice , 2008, The Journal of Neuroscience.

[44]  P. Luiten,et al.  Cerebral microvascular pathology in aging and Alzheimer's disease , 2001, Progress in Neurobiology.

[45]  G. Rosenberg Matrix metalloproteinases and their multiple roles in neurodegenerative diseases , 2009, The Lancet Neurology.

[46]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[47]  T. Saido,et al.  Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease Towards presymptomatic diagnosis, prevention and therapy , 2006, Neuroscience Research.

[48]  R. Deane,et al.  Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid β-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid β-Protein Precursor* , 2004, Journal of Biological Chemistry.

[49]  D. Connor,et al.  Circle of Willis atherosclerosis: association with Alzheimer’s disease, neuritic plaques and neurofibrillary tangles , 2006, Acta Neuropathologica.

[50]  B. Zlokovic,et al.  Substitution at codon 22 reduces clearance of Alzheimer’s amyloid-β peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood , 2002, Neurobiology of Aging.

[51]  R O Weller,et al.  Interrelationships of the pia mater and the perivascular (Virchow-Robin) spaces in the human cerebrum. , 1990, Journal of anatomy.

[52]  C. Betsholtz,et al.  Pericytes and vascular stability. , 2006, Experimental cell research.

[53]  B. Zlokovic The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[54]  J. McLaurin,et al.  Selective targeting of perivascular macrophages for clearance of β-amyloid in cerebral amyloid angiopathy , 2009, Proceedings of the National Academy of Sciences.

[55]  D. Holtzman,et al.  Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[56]  Eric E. Smith,et al.  Amyloid Angiopathy–Related Vascular Cognitive Impairment , 2004, Stroke.

[57]  B. Zlokovic,et al.  The cerebromicrovasculature: a key player in the pathogenesis of Alzheimer's disease. , 2002, Journal of Alzheimer's disease : JAD.

[58]  N. Schuff,et al.  Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. , 2005, Radiology.

[59]  A. Hofman,et al.  Atherosclerosis and risk for dementia , 2007, Annals of neurology.

[60]  P. Wesseling,et al.  Amyloid‐β‐induced Degeneration of Human Brain Pericytes Is Dependent on the Apolipoprotein E Genotype , 2000, Annals of the New York Academy of Sciences.

[61]  Andrew Brooks,et al.  Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype , 2007, Proceedings of the National Academy of Sciences.

[62]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[63]  K. Jellinger,et al.  Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology , 2007, Journal of the Neurological Sciences.

[64]  P. Hof,et al.  The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease , 2004, Neurological research.

[65]  G. Perry,et al.  Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease , 1993, Brain Research.

[66]  R. Deane,et al.  SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells , 2009, Nature Cell Biology.

[67]  B. Zlokovic Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. , 1996, Life Science.

[68]  Hugh Davson,et al.  Physiology and Pathophysiology of the Cerebrospinal Fluid , 1987 .

[69]  M. Tapner,et al.  Soluble Low Density Lipoprotein Receptor-related Protein (LRP) Circulates in Human Plasma* , 1997, The Journal of Biological Chemistry.

[70]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[71]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[72]  K. Jellinger,et al.  Alzheimer’s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy , 2005, Acta Neuropathologica.

[73]  C. Stoeckert,et al.  Defining the mammalian CArGome. , 2005, Genome research.

[74]  A. Hofman,et al.  Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β–amyloid precursor protein gene , 1992, Nature Genetics.

[75]  P. Hedera,et al.  Differential degeneration of the cerebral microvasculature in Alzheimer's disease. , 1995, Neuroreport.

[76]  J. Hardy,et al.  Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). , 1990, Science.

[77]  A. Goate,et al.  Clearance of amyloid-β by circulating lipoprotein receptors , 2007, Nature Medicine.

[78]  M. D. de Leon,et al.  Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[79]  R. Kalaria,et al.  Increased collagen content of cerebral microvessels in Alzheimer's disease , 1995, Brain Research.

[80]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[81]  B. Zlokovic,et al.  beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. , 2000, American journal of physiology. Cell physiology.

[82]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[83]  B. Puig,et al.  RETRACTED: Oxidative damage of 14-3-3 zeta and gamma isoforms in Alzheimer’s disease and cerebral amyloid angiopathy , 2007, Neuroscience.

[84]  R. Deane,et al.  LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. , 2004, Neuron.

[85]  Gregory M. Szilagyi,et al.  Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. , 2008, Archives of neurology.

[86]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.

[87]  P. Wesseling,et al.  Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. , 1999, The American journal of pathology.

[88]  D. Begley,et al.  Structural and functional aspects of the blood-brain barrier. , 2003, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[89]  E. Matsubara,et al.  Isoform‐Specific Effects of Apolipoproteins E2, E3, and E4 on Cerebral Capillary Sequestration and Blood‐Brain Barrier Transport of Circulating Alzheimer's Amyloid β , 1997, Journal of neurochemistry.

[90]  T. Beach,et al.  Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease , 2004, Neurological research.

[91]  T. Iwatsubo,et al.  Major Involvement of Low-Density Lipoprotein Receptor-Related Protein 1 in the Clearance of Plasma Free Amyloid β-Peptide by the Liver , 2006, Pharmaceutical Research.

[92]  J. Parks,et al.  Neurotoxic Aβ peptides increase oxidative stress in vivo through NMDA‐receptor and nitric‐oxide‐synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro , 2001, Journal of neurochemistry.

[93]  R. Koehler,et al.  Dopamine Receptor Modulation of Hypoxic—Ischemic Neuronal Injury in Striatum of Newborn Piglets , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[94]  Thomas Wisniewski,et al.  Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.

[95]  Peter J. Lenting,et al.  LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms , 2004, Neuron.

[96]  E. Zhang,et al.  Perivascular cells act as scavengers in the cerebral perivascular spaces and remain distinct from pericytes, microglia and macrophages , 2004, Acta Neuropathologica.

[97]  Don L. Armstrong,et al.  Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease , 2005, Nature Medicine.

[98]  R. Deane,et al.  ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration , 2008, Nature Neuroscience.

[99]  C. Iadecola Neurovascular regulation in the normal brain and in Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[100]  A. Drzezga,et al.  Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[101]  W. V. Van Nostrand,et al.  Pathogenic Aβ induces the expression and activation of matrix metalloproteinase‐2 in human cerebrovascular smooth muscle cells , 2003 .

[102]  K. Welsh-Bohmer,et al.  Vascular Smooth Muscle Actin Is Reduced in Alzheimer Disease Brain: A Quantitative Analysis , 2004, Journal of neuropathology and experimental neurology.

[103]  Hiroshi Matsuda,et al.  The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT , 2005, NeuroImage.

[104]  A. Hofman,et al.  Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam study , 2005, Annals of neurology.

[105]  Uwe Haberkorn,et al.  Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease , 2007, Psychiatry Research: Neuroimaging.

[106]  C. Geula,et al.  Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease , 2007, Nature Medicine.

[107]  H. Vinters,et al.  Microvasculature in brain biopsy specimens from patients with Alzheimer's disease: an immunohistochemical and ultrastructural study. , 1994, Ultrastructural Pathology.

[108]  P. Reynolds,et al.  Midkine Is Regulated by Hypoxia and Causes Pulmonary Vascular Remodeling* , 2004, Journal of Biological Chemistry.

[109]  B. Zlokovic,et al.  Kinetics and Na independence of amino acid uptake by blood side of perfused sheep choroid plexus. , 1990, The American journal of physiology.